Stay updated with breaking news from Evogene Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biomica Ltd., a subsidiary of Evogene Ltd. (EVGN), Thursday announced positive data from its ongoing Phase 1 trial of microbiome-based immuno-oncology candidate, BMC128, in combination with nivolumab, for the treatment of patients with non-small cell lung cancer or NSCLC, melanoma, or renal cell carcinoma or RCC.
StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN – Free Report) in a report published on Saturday morning. The firm issued a sell rating on the biotechnology company’s stock. Evogene Price Performance EVGN stock opened at $0.72 on Friday. Evogene has a 1-year low of $0.45 and a 1-year high of $1.44. The business has […]
Research analysts at StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN – Get Free Report) in a research note issued on Saturday. The brokerage set a “sell” rating on the biotechnology company’s stock. Evogene Stock Up 1.3 % Shares of EVGN stock opened at $0.66 on Friday. Evogene has a 12 month low of $0.45 […]
Evogene (NASDAQ:EVGN – Get Free Report) will be posting its quarterly earnings results before the market opens on Thursday, May 23rd. Individual that are interested in registering for the company’s earnings conference call can do so using this link. Evogene (NASDAQ:EVGN – Get Free Report) last posted its quarterly earnings results on Thursday, March 7th. […]
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF...